AIM
CRBP icon

Advantage Investment Management’s Corbus Pharmaceuticals CRBP Stock Holding History

Advantage Investment Management’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$5K Hold
33
– – ﹤0.01% 758
2019
Q2 		$7K Hold
33
– – 0.01% 714
2019
Q1 		$7K Hold
33
– – 0.01% 697
2018
Q4 		$6K Hold
33
– – ﹤0.01% 748
2018
Q3 		$8K Hold
33
– – 0.01% 747
2018
Q2 		$5K Buy
+33
New +$6K ﹤0.01% 762

Other funds holding CRBP

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Advantage Investment Management's CRBP Position: Q3 2019 in Review

Advantage Investment Management held its Corbus Pharmaceuticals (CRBP) position steady in Q3 2019 at 33 shares worth $5K. The position accounts for ﹤0.01% of the portfolio, ranked #758.

Advantage Investment Management first reported a position in CRBP in Q2 2018 and has held it in 6 quarters since. The position peaked at $8K in Q3 2018. 103 funds tracked by Wall St. Rank hold CRBP as of Q3 2019.

  • Advantage Investment Management held 33 shares of Corbus Pharmaceuticals worth $5K as of Q3 2019.
  • Advantage Investment Management left its Corbus Pharmaceuticals share count unchanged in Q3 2019.
  • Corbus Pharmaceuticals made up ﹤0.01% of Advantage Investment Management's portfolio in Q3 2019, its #758 holding.
  • Advantage Investment Management first reported a position in Corbus Pharmaceuticals in Q2 2018 and has held it in 6 quarters since.
  • Advantage Investment Management's Corbus Pharmaceuticals position peaked at $8K in Q3 2018.
  • 103 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q3 2019.

Based on Advantage Investment Management's 13F filing for Q3 2019, filed 8 Oct 2019.